[email protected]   +1 (304) 470-2225

Cluster of Differentiation 47 (CD47) Inhibitors – Pipeline Analytics-2021

$2,500.00$7,500.00

Cluster of Differentiation 47 (CD47) Inhibitor’s report covers the CD47 market opportunity providing Key Competitive Analysis, 30+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, and therapy area. CD47 inhibitors reports adds a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as monotherapy and combinations.

Clear
SKU: MM202041 Category:

Description

Targeting Cluster of Differentiation 47 (CD47), a ‘marker-of-self’ protein, mostly overexpressed across all the tumor types, is emerging as a novel potent macrophage immune checkpoint for cancer immunotherapy and it has generated a big interest among industry leaders to target CD47 at different points in its signaling pathway for the purpose of cancer treatment. Currently, multiple therapeutic biologicals are under development targeting CD47-SIRPα protein in different developmental phases and therapy areas like oncology, autoimmune and CNS diseases with approximately 20 candidates currently under evaluation in clinical and preclinical studies.

The report provides an in-depth analysis of key pipeline products by segments like Stage of development, Company and Therapy Area. It also provides in-depth analyzes of CD47 Inhibitor’s profiles covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy area, investments, and acquisition trends as well as estimated clinical and regulatory timeline of Phase III and Phase II therapeutic candidates.

As per Mellalta Meets analysis, the development pipeline is full of directly acting specific and bispecific CD47 inhibitors or indirect modulators of the CD47 signaling pathway consisting of molecules like monoclonal antibodies, fusion proteins, and small molecules. At least 35 distinct molecules targeting the CD47 pathway are in clinical development. Clinical and regulatory timelines of later stage products like Magrolimab (Gilead Sciences /Forty Seven), a humanized anti-CD47 monoclonal antibody known as hu5F9-G4 and RRx-001 (EpicentRx/RadioRx) are the major highlights of the report along with description of their clinical trial analysis.

Key Highlights of Cluster of Differentiation 47 (CD47) Inhibitors Report

  • There are ~17 products in the Phase-I stage of development, representing 49% of the total share of the developing CD47 inhibitors landscape.
  • The pipeline of CD47 is dominated by biotech companies headquartered in the United States with the American companies holding the top ten positions. They represent ~45% of all the pipeline CD47 in clinical stages.
  • Oncology represents ~ 97% of the total CD47 therapies while the therapy areas namely Dermatology occupy the remaining 3% of the CD47 trials.

CD47 Inhibitors Regulatory Approvals

  • To be continued…

Report Coverage:

  • Indication Prioritisation: Cluster of Differentiation 47 (CD47) Inhibitors market potential based on Indications
  • Business Transactions & Strategies: Key collaborations and deal values
  • Cluster of Differentiation 47 (CD47) Inhibitors Pipeline Development: Product Profiles, Clinical Trials & Results
  • Cluster of Differentiation 47 (CD47) Inhibitors Acquisition Targets
  • Cluster of Differentiation 47 (CD47) Inhibitors Competitive Intelligence
  • Recent & Upcoming events

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • Cluster of Differentiation 47 (CD47) Inhibitors Report Overview
  • The Cluster of Differentiation 47 (CD47) Target BACKGROUND
    • Cluster of Differentiation 47 (CD47) Overview
    • Advances in Anti-Tumor Treatments Targeting the CD47
    • Relationship Between CD47 Signaling Pathways and Diseases
  • Cluster of Differentiation 47 (CD47) PIPELINE ANALYSIS
    • Pipeline Products by Stage of Development
    • Cluster of Differentiation 47 (CD47) Competitive Landscape
    • Pipeline Products by Company
    • Pipeline Products by Therapy Area
    • Cluster of Differentiation 47 (CD47) Clinical & Regulatory Timelines
  • Cluster of Differentiation 47 (CD47) LICENSING, ACQUISITION AND COLLABORATION DEALS
    • Cluster of Differentiation 47 (CD47) Licensing, Acquisition and Deal values
    • Cluster of Differentiation 47 (CD47) Licensing by Transaction type and Total amount size by stages of development
  • Cluster of Differentiation 47 (CD47) Inhibitors – Pipeline Landscape
    • Profile Comparisons At–a–glance
    • CD47 PIPELINE DRUG PROFILES & CLINICAL TRIAL ANALYSIS
      • Phase III
      • Gilead Sciences /Forty-SevenMagrolimab
        • Product Profile & Description
        • Clinical Trials
      • EpicentRx/RadioRxRRx-001
        • Product Profile & Description
        • Clinical Trials
      • Phase II 
      • ALX Oncology: ALX-148
        • Product Profile & Description
        • Clinical Trials
      • Waterstone Hanxbio: HX-009
        • Product Profile & Description
        • Clinical Trials
      • Phase I/II
      • KAHR medicalDSP-107
        • Product Profile & Description
        • Clinical Trials
      • CSPC Pharmaceutical Group Co./Conjupro BiotherapeuticsJMT-601
        • Product Profile & Description
        • Clinical Trials
      • AbbVie/I-MAb BiopharmaLemzoparlimab
        • Product Profile & Description
        • Clinical Trials
      • Arch Oncology: AO-176
        • Product Profile & Description
        • Clinical Trials
      • Akeso BiopharmaAK-117
        • Product Profile & Description
        • Clinical Trials
      • Phase I
      • ImmuneOnco BiopharmaIMM-01
        • Product Profile & Description
        • Clinical Trials
      • Chia Tai Tianqing Pharmaceutical Group Co.: TQB-2928
        • Product Profile & Description
        • Clinical Trials
      • Shattuck Labs: SL-172154
        • Product Profile & Description
        • Clinical Trials
      • Trillium TherapeuticsOntorpacept
        • Product Profile & Description
        • Clinical Trials
      • Trillium TherapeuticsTTI-622
        • Product Profile & Description
        • Clinical Trials
      • Surface Oncology: Urabrelimab
        • Product Profile & Description
        • Clinical Trials
      • Innovent BiologicsLetaplimab
        • Product Profile & Description
        • Clinical Trials
      • Innovent BiologicsIBI-322
        • Product Profile & Description
        • Clinical Trials
      • ImmuneOnco BiopharmaIMM-0306
        • Product Profile & Description
        • Clinical Trials
      • ImmuneOnco BiopharmaIMM-2902
        • Product Profile & Description
        • Clinical Trials
      • Zai Lab LimitedZL-1201
        • Product Profile & Description
        • Clinical Trials
      • SWISS BIOPHARMAsB24M
        • Product Profile & Description
        • Clinical Trials
      • Bristol-Myers Squibb/Celgene: CC-90002
        • Product Profile & Description
        • Clinical Trials
      • Sorrento TherapeuticsSTI-6643
        • Product Profile & Description
        • Clinical Trials
      • ImmuneOncia TherapeuticsIMC-002
        • Product Profile & Description
        • Clinical Trials
      • TG TherapeuticsTG-1801
        • Product Profile & Description
        • Clinical Trials
      • PfizerPF-07257876
        • Product Profile & Description
        • Clinical Trials
      • Preclinical
      • Immuneonco BiopharmaceuticalsIMM-2505
        • Product Profile & Description
        • Clinical Trials
      • Light Chain BioscienceNI-1801
        • Product Profile & Description
        • Clinical Trials
      • Hanmi Pharmaceutical: PD-L1/CD47 BsAb
        • Product Profile & Description
        • Clinical Trials
      • LynkCellLYN-301
        • Product Profile & Description
        • Clinical Trials
      • Abpro TherapeuticsABP-500
        • Product Profile & Description
        • Clinical Trials
      • Abpro TherapeuticsABP-160
        • Product Profile & Description
        • Clinical Trials
      • Bio-Thera SolutionsBAT-7104
        • Product Profile & Description
        • Clinical Trials
      • Aurigene Discovery TechnologiesAUR-105
        • Product Profile & Description
        • Clinical Trials
      • Beijing hanmi pharmaceuticalBH-3012
        • Product Profile & Description
        • Clinical Trials
      • SWOT Analysis
      • Appendix

Companies Coverage

  • AbbVie Inc./I-MAb Biopharma Co., Ltd.
  • Abpro Therapeutics
  • Akeso Biopharma Co., Ltd
  • ALX Oncology
  • Arch Oncology Inc.
  • Aurigene Discovery Technologies Limited
  • Beijing hanmi pharmaceutical co ltd
  • Bio-Thera Solutions, Ltd.
  • Bristol-Myers Squibb/Celgene
  • Chia Tai Tianqing Pharmaceutical Group Co.
  • CSPC Pharmaceutical Group Co./Conjupro Biotherapeutics
  • EpicentRx Inc./RadioRx
  • Gilead Sciences Inc./Forty Seven
  • Hanmi Pharmaceutical co., ltd.
  • ImmuneOncia Therapeutics, Inc.
  • Immuneonco Biopharmaceuticals Co. ltd
  • Innovent Biologics, Inc.
  • KAHR Medical
  • Light Chain Bioscience
  • LynkCell, Inc.
  • Pfizer
  • Shattuck Labs Inc.
  • Sorrento Therapeutics, Inc.
  • Surface Oncology, Inc.
  • SWISS BIOPHARMA
  • TG Therapeutics, Inc.
  • Trillium Therapeutics Inc.
  • Waterstone Hanxbio, Inc.
  • Zai Lab Limited
  • Others
Name
Email
Phone
Enquiry

Get In Touch

Let's keep the conversation going